IL17A and neoplasm: IL-17 drives higher expression of inhibitory receptors such as PD-1 and TIM-3 on CD8+ T cells, and also reduces PD-L1 expression on tumor cells; together, these changes further suppress T-cell activity and mediate ICI resistance [88].